Skip to Content

Moderna Inc MRNA Stock Quote

| Rating as of


Last close prices updated as of Jan 27, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 189.35
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Large Blend
  • Day Range 188.28  –  193.52
  • Year Range 115.03  –  217.25
  • Market Cap 72.7446 Bil
  • Volume / Avg 3.3 Mil /  5.3 Mil
  • Price / Sales 3.86
  • Price / Book 4.04
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis MRNA

Currency in USD
MRNA is Undervalued at a 29% Discount.
MRNA is 4 at a 29% -29.

1-Star Price

> 465.50

5-Star Price

< 133.00

Economic Moat


Trend: Positive

Capital Allocation


Maintaining Our $266 Moderna Fair Value Estimate Following Promising Phase 3 RSV Vaccine Data

Karen Andersen Sector Strategist

Analyst Note

| Karen Andersen |

We’re maintaining our $266 fair value estimate for Moderna following positive phase 3 data from the first interim analysis of the firm’s respiratory syncytial virus vaccine, mRNA-1345. While we’ve raised our assumed probability of approval for the vaccine to 70% from 50%, we’ve also boosted our long-term assumptions for annual research and development expenses following the firm’s massive $4.5 billion guidance for 2023 R&D expenses at a recent healthcare conference. This spending would be significantly above the roughly $3.3 billion spent in 2022, so we’re boosting our long-term annual R&D expenses to roughly $3.5 billion annually from our prior estimate of $3 billion (still roughly 20% of sales by 2031). The positive RSV data comes on the heels of positive data for Merck and Moderna’s personalized melanoma vaccine. We continue to think the market underestimates the potential of Moderna’s mRNA technology to address multiple types of diseases in both prevention and treatment. However, we think Moderna is still in the process of building a moat, as multiple other firms could have the technology to compete, and the overall market opportunity remains unclear. We look forward to more early-stage data from Moderna’s rare-disease programs this year, which we think could open up a very broad opportunity, but due to the higher-risk nature of the programs, we currently assume only a 25% probability of approval.

Moderna plans to file for approval of its RSV vaccine in the first half of 2023, putting it potentially third to market behind Pfizer and GSK, which both expect to gain regulatory approval for their own RSV vaccines in the older adult population (over the age of 60) by May. Johnson & Johnson could also compete but has yet to disclose phase 3 data for its own vaccine. Regardless, Moderna stands out as the only mRNA-based vaccine in this wave of potential new vaccines.

Key Statistics MRNA

Company Profile MRNA

Business Description

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

200 Technology Square
Cambridge, MA, 02139
Industry Biotechnology
Employees 2,700

Related Articles MRNA

FAQs for Moderna Inc Stock

No. MRNA does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

MRNA’s market cap is 72.74 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

MRNA’s stock style is Large Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

MRNA’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare MRNA’s historical performance against its industry peers and the overall market.